About this trial
To evaluate if rovalpituzumab tesirine improves progression-free and overall survival.
This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and multicenter study. ED SCLC patients who demonstrate ongoing clinical benefit at the completion of 4 cycles of first-line platinum-based chemotherapy will be randomly assigned in a 1:1 ratio to receive rovalpituzumab tesirine or placebo.
Patients with extensive-stage Small Cell Lung Cancer (ED SCLC) with ongoing clinical benefit following completion of 4 cycles of first-line platinum-based chemotherapy.
Where’s this trial being run?Beaumont Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU).
|Principal Investigator:||Dr Linda Coate (University Hospital Limerick)|
Global: April 2017
Ireland: September 2017
|Global Recruitment Target:||711|
|Ireland Recruitment Target:||12|